What JUNO Genetics does

Juno Genetics is a privately held specialty diagnostics laboratory that provides preimplantation genetic testing (PGT) for patients undergoing in vitro fertilization (IVF). Operating as Juno Genetics, US Inc. with its US headquarters in Basking Ridge, New Jersey and a firmographic base in Oxford, United Kingdom, the company serves two primary segments: IVF patients referred by fertility healthcare providers, and the clinics and reproductive endocrinologists who direct those referrals. Service is delivered through a B2B2C model in which Juno is embedded into clinic workflows, with direct patient scheduling and genetic counseling layered on top of laboratory testing.

The company's core offering is the PGTseq franchise of three tests: PGTseq-A for aneuploidy screening, PGTseq-M for customized single-gene disorder testing, and PGTseq-SR for chromosome rearrangement testing. The underlying platform combines targeted next-generation sequencing (tNGS) with single nucleotide polymorphism (SNP) assays, explicitly avoiding whole-genome amplification. Juno claims greater than 98% accuracy in whole-chromosome aneuploidy and unbalanced rearrangement screening, supported by two validation studies: a non-selection embryo transfer study and a blinded rebiopsy study showing 97-99% concordance. Cumulative testing volume is stated in the hundreds of thousands of embryos, generating a meaningful clinical-outcome dataset.

Juno generates revenue through professional-services fees for laboratory testing, with pricing not publicly disclosed. Distribution runs through IVF clinic referrals across five regional markets — USA, UK, Spain, Italy and broader Europe — each with its own localized website. Patient-facing capabilities include board-certified genetic counseling appointments and direct contact channels, but the company does not appear to publish enterprise contract terms, recurring-revenue metrics, or funding history. Strategic positioning emphasizes clinical evidence and validation depth over marketing-driven claims.

Name

JUNO Genetics

Legal name

Juno Genetics, US Inc.

Website

https://junogenetics.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

Juno Genetics is a specialty diagnostics laboratory providing preimplantation genetic testing (PGTseq-A, PGTseq-M, PGTseq-SR) using targeted NGS and SNP assays to IVF patients and fertility clinics across the US, UK, Spain, Italy and broader Europe.

Ownership category

akta.pro rank

Product category

Reproductive Genetic Testing

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

akta.pro secondary industries

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Preimplantation genetic testing
• IVF genetic screening
• Aneuploidy screening services
• Single gene disorder testing
• Chromosome rearrangement testing

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Preimplantation Genetic Testing Services: Laboratory diagnostic services providing PGTseq-A, PGTseq-M, and PGTseq-SR testing for IVF patients. Services are provided to patients undergoing fertility treatments through referral from healthcare providers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

JUNO Genetics is a specialized reproductive diagnostics laboratory that performs preimplantation genetic testing (PGT) on embryo biopsy samples from IVF cycles. Its commercial offerings consist of three proprietary genetic tests — PGTseq-A (aneuploidy screening), PGTseq-M (single gene disorder testing), and PGTseq-SR (structural chromosome rearrangement testing) — delivered together with genetic counseling services to fertility clinics, reproductive endocrinologists, and their patients.

Product overview

Juno Genetics operates a state-of-the-art laboratory specializing in preimplantation genetic testing (PGT) with three core genetic tests: PGTseq-A (aneuploidy screening), PGTseq-M (single gene disorder testing), and PGTseq-SR (chromosome rearrangement testing). These tests are designed to inform IVF decisions by assessing embryo genetic health. The company also provides genetic counseling services as part of its patient support offering. All three PGT tests utilize targeted next-generation sequencing (tNGS) technology and SNP analysis for enhanced accuracy and quality control.

Differentiator

Problem solved

Functional benefit

Products and services

• PGTseq-A Preimplantation Genetic Testing for Aneuploidy (PGT-A) using targeted next-generation sequencing (tNGS) and SNP assays to identify embryos with the correct number of chromosomes during IVF; reported as greater than 98% accurate in screening for whole chromosome aneuploidy and including SNP-based molecular fertilization check, contamination detection, and embryo sibling QC. Designed for IVF patients referred by fertility clinics and reproductive endocrinologists.
• PGTseq-M Customized single gene disorder testing that is designed per family to detect genetic alterations associated with specific monogenic disorders in embryos prior to transfer during an IVF cycle; all embryos tested also receive aneuploidy screening with PGTseq-A. Targeted at individuals or couples with a known increased risk of transmitting a specific genetic condition.
• PGTseq-SR Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR) performed via targeted next-generation sequencing (tNGS) to determine whether embryo biopsies have extra or missing chromosomal material in patients carrying a chromosome rearrangement; reported as greater than 98% accurate and bundling PGTseq-A aneuploidy screening.
• Genetic Counseling Services Comprehensive patient support service offering access to board-certified genetic counselors on staff, easy scheduling, and payment assistance throughout the preimplantation genetic testing process; intended for IVF patients undergoing PGT through Juno Genetics.

Quantifiable outcome

• Greater than 98% accuracy in screening for whole chromosome aneuploidy (PGTseq-A) and unbalanced chromosome rearrangements (PGTseq-SR)
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Top IVF Clinics and Reproductive EndocrinologistscoreStrategic or Co-development PartnerStrong collaboration with top IVF clinics and reproductive endocrinologists to provide preimplantation genetic testing services. Juno works closely with fertility healthcare providers in supporting patients undergoing IVF treatments.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Natera: Public US genetics company (NASDAQ: NTRA) with a dedicated reproductive health franchise including Empower (PGx), Spectrum PGT-A/M, and Vistara single-gene PGT. Competes head-to-head with Juno on IVF clinic contracts in the US.
• Genomic Prediction: US-based PGT laboratory offering PGT-A and polygenic PGT services. Direct competitor on aneuploidy screening with overlapping IVF clinic customer base, though differentiated by focus on polygenic risk scoring.
• Progenesis: PGT laboratory offering PGT-A and PGT-SR to IVF clinics. Smaller direct peer with similar tNGS-based technology approach and comparable B2B clinic distribution model to Juno Genetics.
• CooperSurgical (CooperGenomics): CooperSurgical's CooperGenomics division provides PGT-A, PGT-M, and PGT-SR services through IVF clinics globally. Directly comparable product suite and clinic-channel distribution model to Juno Genetics.
• Igenomix (Vitrolife): Spanish-origin PGT and reproductive genetics laboratory, acquired by Vitrolife in 2021 for ~$1.2B. Direct competitor offering PGT-A, PGT-M, and PGT-SR with international clinic network reach closely matching Juno's product portfolio and B2B2C IVF clinic model.

Broad incumbents

• Quest Diagnostics: Large US clinical laboratory offering women's health and reproductive genetics panels including NIPT and carrier screening. Broader incumbent that competes for the same fertility clinic referral channels, though not a PGT specialist.
• BioReference Laboratories (OPKO Health): US clinical laboratory providing reproductive and women's health genetic testing services. Larger incumbent with established hospital and clinic relationships that overlap with Juno's IVF clinic customer base.
• Reprogenetics (Labcorp): Reprogenetics, now part of Labcorp, has historically been one of the largest PGT providers worldwide. Broader incumbent with deep IVF clinic penetration and significantly larger clinical lab infrastructure than Juno.

Emerging players

• Myome Sciences: Emerging PGT provider focused on polygenic and single-gene embryo assessment. Partial product overlap with Juno's PGTseq-M and chromosome-level tests, targeting similar reproductive endocrinology customers.

Others

• Thermo Fisher Scientific (Reproductive Health): Supplies NGS instruments, reagents, and Ion Torrent-based PGT workflows used by many IVF genetics labs. Functions as an enabling technology provider to the PGT category in which Juno competes rather than a direct clinical competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JUNO Genetics